52128-35-5 Usage
Uses
Used in Antineoplastic Applications:
Trimetrexate is used as an antineoplastic agent for the treatment of colorectal cancer, head and neck cancer, and non-small cell lung cancer (NSCLC). The drug selectively inhibits Streptococcus mutans through targeting dihydrofolate reductase (DHFR), which plays a crucial role in the synthesis of thymidylate, an essential component for DNA replication and cell proliferation. By inhibiting this enzyme, Trimetrexate disrupts the rapid cell division and growth associated with cancer cells, thus exerting its antineoplastic effects.
Used in Pneumocystis carinii Treatment:
Trimetrexate is used as an anti-infective agent for the treatment of Pneumocystis carinii, a fungal infection that primarily affects patients with weakened immune systems, such as those with AIDS. The drug exhibits antiprotozoal activity against Trypanosoma cruzi, the parasite responsible for Chagas disease, further expanding its therapeutic applications.
Used in Combination Therapy:
Trimetrexate is used in combination therapy with folinic acid, similar to the administration of methotrexate with calcium leucovorin in cancer chemotherapy. This combination helps to reduce the toxicity and side effects associated with high doses of Trimetrexate while maintaining its therapeutic efficacy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Trimetrexate is used as an active pharmaceutical ingredient for the development of drugs targeting various types of cancer and infectious diseases. Its unique mechanism of action and selectivity for specific enzymes make it a valuable compound in the fight against cancer and other related conditions.
Mechanism of action
Trimetrexate is considered to be a nonclassical folate antagonist, whereas methotrexate, the
structurally similar analogue of TMQ, is a classical folate antagonist. The difference between
these two drugs is that methotrexate, with its polar glutamate side chain, is transported into the
cell via a carrier-mediated transport system, whereas TMQ, without the glutamate moiety, is
absorbed by the cell via a passive diffusion. Once in the cell, TMQ inhibits DHFR. Trimetrexate
binds to Pneumocystis cari nii DHFR 1,500 times more strongly than trimethoprim and somewhat
more strongly than methotrexate. It also has been reported that TMQ readily enters the P. carinii
cell because of the lipophilic nature of this drug. Methotrexate and leucovorin are not able to
enter the cell, however, because the cell membrane of P. carinii does not possess the transporter
protein.
Clinical Use
Trimetrexate, when combined with the cytoprotective agent leucovorin, is more effective and better
tolerated than pentamidine in the treatment of PCP. Because the first- and second-line agents
are successful in only 50 to 75% of these cases, and because adverse reactions severely limit the
use of some of the older agents, TMQ may offer some advantages in treatment. Trimetrexate is
administered by IV infusion over 60 to 90 minutes and should be combined with the cytoprotective
drug leucovorin. The leucovorin protects against bone marrow suppression and against renal and
hepatic dysfunction. Leucovorin administration should continue for 72 hours after the last dose of
TMQ. Additionally, TMQ has been reported to be effective in the treatment of Chagas' disease.
Check Digit Verification of cas no
The CAS Registry Mumber 52128-35-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,1,2 and 8 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 52128-35:
(7*5)+(6*2)+(5*1)+(4*2)+(3*8)+(2*3)+(1*5)=95
95 % 10 = 5
So 52128-35-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H23N5O3.3ClH/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;;;/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);3*1H
52128-35-5Relevant articles and documents
Thermally stable trimetrexates and processes for producing the same
-
, (2008/06/13)
The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P+E,ovs 1+EE (#2) and having a triclinic cell with dimensions of about a=7.699 ANGSTROM , b=9.606 ANGSTROM and c=13.012 ANGSTROM is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.
Insecticidal substituted-2,4-diaminoquinazolines
-
, (2008/06/13)
An insecticidal composition comprising, in admixture with an agriculturally acceptable carrier, an insecticidally effective amount of a 2,4-diaminoquinazoline compound of the formula: STR1 wherein R1, R2, R6, R7, W, X, Y, and Z are as defined herein; methods of using the same; novel 2,4-diaminoquinazolines per se; and intermediates in the preparation thereof.
